test systems / chemical/pharmacological class / pharmaceuticals / gene products / appropriate test systems / marketed pharmaceuticals / chemical entities / physiological systems / pharmaceutical-induced prolongation / heterologous expression systems / /
Repeated administration / U.S. Department of Health and Human Services / Food and Drug Administration Center for Drug Evaluation and Research / Training and Communication Division of Drug Information / Food and Drug Administration / office of Training / HFD-240 Center for Drug Evaluation / U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research / European Union / ICH Steering Committee / Center for Biologics Evaluation and Research / Center for Biologics Evaluation and Research Food and Drug Administration / office of Communication / Training and Manufacturers Assistance / / /
Guidance for Industry S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals